RankingsPricing
  1. US-listed companies
  2. ACADIA PHARMACEUTICALS INC
  3. Financials
  4. Cash and cash equivalents

ACADIA PHARMACEUTICALS INCACAD

Market cap
$3.9B
P/E ratio
SummaryFinancials
Period EndCash and cash equivalents (Million USD)YoY (%)
Dec 31, 2024320+69.40%
Dec 31, 2023189+64.27%
Dec 31, 2022115-22.10%
Dec 31, 2021147-54.78%
Dec 31, 2020326+71.88%
Dec 31, 2019190+40.76%
Dec 31, 2018135+94.13%
Dec 31, 201769-57.57%
Dec 31, 2016164+60.20%
Dec 31, 2015102+65.13%
Dec 31, 201462+428.35%
Dec 31, 201312-79.78%
Dec 31, 201258+740.46%
Dec 31, 20117

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)